Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.39 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18631195 | 1.00 | CNR2 (0.39) | CNR2CNR1KARS1ABCB11HTR1A | |
| SCHEMBL18631271 | 0.90 | CNR2 (0.38) | CNR2CNR1KARS1 | |
| SCHEMBL18631272 | 0.90 | CNR2 (0.38) | CNR2CNR1KARS1 | |
| SCHEMBL18650853 | 0.88 | ALDH1A1 (0.40) | CNR2CNR1 | |
| SCHEMBL18630887 | 0.88 | — | — | |
| SCHEMBL18630890 | 0.88 | — | — | |
| SCHEMBL18650869 | 0.88 | CNR2 (0.39) | CNR2CNR1ABCB11HTR1AADRA2A | |
| SCHEMBL18631184 | 0.87 | RAF1 (0.38) | CNR2CNR1ABCB11HTR1AADRA2A | |
| SCHEMBL18631185 | 0.87 | RAF1 (0.38) | CNR2CNR1ABCB11HTR1AADRA2A | |
| SCHEMBL18631189 | 0.87 | CNR2 (0.38) | CNR2CNR1KARS1ABCB11HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350177-B1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-07-07 | — | — | EP | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2018-08-28 | — | — | US | disclosed |
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-23 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180237426-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CNR2 3727/4885CNR1 3441/4885KARS1 360/4885 |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CNR2 3727/4885CNR1 3441/4885KARS1 360/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | CNR2 3727/4885CNR1 3441/4885KARS1 360/4885 |
| US-10059701-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | CNR2 3727/4885CNR1 3441/4885KARS1 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.